

Guoqing Qian
August 2025 - August 2026
Assistant Professor
(903)877-8358
guoqing.qian@uthct.edu

CONTACT INFORMATION

Lab A-8 Biomedical Research Center
11937 US Highway 271
Tyler, Texas 75708

DEGREES

2012 Ph.D., Toxicology, The University of Georgia, Athens, Georgia, United States
Dissertation: Integrative toxicological evaluation of aflatoxin B1 exposure in Fischer 344 rats and biomarker-based exposure assessment of aflatoxin B1 in human populations

POST-GRADUATE TRAINING

Post-Doctorate, Emory University, Cancer Biology, Atlanta, Georgia, United States, January 2013, February 2018

ACADEMIC APPOINTMENTS

Assistant Professor, CMB, UT Tyler School of Medicine, 2019-07-01, 2024-08-31

Associate Professor, Cellular and Molecular Biology, The University of Texas at Tyler, Tyler, Texas, Tenure (if applicable): Tenured, 2024-09-01, 2031-08-31

HONORS AND AWARDS

September 2025

DICE Award, UT Tyler School of Medicine, Project title: Novel role of DOCK2 in pulmonary fibrosis

Judge of scientific posters at 41st Southern Biomedical Engineering Conference, UT Tyler, International meeting

PROFESSIONAL MEMBERSHIPS

National

April 2026 - Ongoing

Chinese-American Lung Association [Responsibility: Member]

November 2022 - Ongoing

American Thoracic Society [Responsibility: Member]

September 2022 - Ongoing

American Heart Association [Responsibility: Member]

SERVICE ON COMMITTEES

UTTSOM**June 2026 - Ongoing**

Biotech Thesis committee Chair, Subcommittee : Parsa Torabi [Responsibility: Chair]

April 2026 - Ongoing

Faculty Advisory Committee [Responsibility: Member]

March 2026 - Ongoing

PhD Qualify Exam 2 Committee [Responsibility: Member]

December 2023 - August 2025

Biotech Thesis Committee, Subcommittee : Javier Lopez [Responsibility: Member]

May 2022 - Ongoing

Biotech Program Curriculum Committee [Responsibility: Member by Nomination]

December 2019 - Ongoing

Faculty candidate search committee [Responsibility: Interview of faculty candidate]

International**June 2026 - June 2026**

AHA abstract review committee [Responsibility: Member by Nomination]

February 2026 - February 2026

Grant Review panel for ImPROGRESS Proposals [Responsibility: Member]

EDITORIAL/BOARD APPOINTMENTS AND RESPONSIBILITIES

May 2026 - Ongoing

Editorial Board member of Frontiers in Bioscience-Landmark, Editorial board member

January 2021 - Ongoing

Editorial board member of Frontiers in Pharmacology, Frontiers in Pharmacology, Associate Editor, Respiratory Pharmacology Section

TEACHING ACTIVITIES

Title	Setting	Level of Learner	Number of Learners	Contact Hours	Type of Learning Activity	Teaching Methods	Start Month	End Month
IBMS6315 - Transmembrane Signaling	Elective	Doctoral/Master	4	18	Series	Lecture, Small Group (e.g.: Case-based discussion)	May 2026	Ongoing
BIOT5222 Advanced Metabolism	Course	Doctoral/Master	11	9	Series	Lecture	January 2022	Ongoing
BIOT5222L Advanced Metabolism Lab	Lab	Doctoral/Master	11	8	Series	Laboratory	January 2022	Ongoing
BIOT 6311 - Biotechnology I	Course, Lab	Doctoral/Master	11	16	Series	Lecture, Laboratory	January 2022	Ongoing
BIOT 5310 - Fundamentals of Biomedical Research	Course	Doctoral/Master	11	0.5	Single Session	Lecture	September 2020	Ongoing
BIOT5132 - Critical Reading II	Course	Doctoral/Master	12	1	Single Session	Seminar/Journal Club/Grand Rounds	September 2019	Ongoing

CURRICULUM DEVELOPMENT

Curriculum Name/Topic	Your Role and Degree of Responsibility	Curriculum Length	Level of Learner	Number of Learners	Start Month	End Month
IBMS6315 Transmembrane Signaling: RTK signaling and Wnt Signaling	Developer	Elective	Doctoral/Master	4	May 2026	Ongoing
BIOT 6311 Biotechnology I/qPCR lecture & lab	Developer	Session(s)/lab(s)	Doctoral/Master	11	August 2022	Ongoing
BIOT5222 Advanced Metabolism: Cancer and Metabolic Disease	Developer	Session(s)/lab(s)	Doctoral/Master	11	January 2022	Ongoing

ADVISING/MENTORING/COACHING

Name of Individual	Level of Training	Purpose/Objective	Mentoring/Advising Activities	Start Month	End Month
Ava Le	Undergraduate	Development of individual	Formal, Research mentor/advisor/coach	July 2026	July 2026
Bon Kim	Undergraduate	Development of individual	Formal, Research mentor/advisor/coach	July 2026	July 2026
Ronggui Dai	Graduate	Scholarly work	Formal, Research mentor/advisor/coach	June 2026	Ongoing
Atrayee Bhattacharya	Faculty/Professional Colleague	Development of individual	Formal, Research mentor/advisor/coach	April 2026	Ongoing
Andrea Sanchez Lozoya	Undergraduate	Development of individual	Formal, Student career advising/coaching	February 2026	Ongoing
Karmina Galeon	Doctoral	Career advancement of individual	Formal, Research mentor/advisor/coach	November 2025	May 2026
Grace Lee	Undergraduate	Career advancement of individual	Formal, Research mentor/advisor/coach	October 2025	January 2026
Brian Kempe	Graduate	Scholarly work	Formal, Research mentor/advisor/coach	October 2025	October 2025
Matthew Rogers	Undergraduate	Career advancement of individual	Formal, Research mentor/advisor/coach	October 2024	August 2025
Junlin Shi	Fellow or Post-Doc	Scholarly work	Formal, Research mentor/advisor/coach	June 2024	Ongoing
Ashoka Kumar	Fellow or Post-Doc	Development of individual	Formal, Research mentor/advisor/coach	June 2024	Ongoing
Qinying Li	Graduate	Scholarly work	Formal, Research mentor/advisor/coach	April 2024	February 2026
Javier Lopez	Graduate	Scholarly work	Formal, Research mentor/advisor/coach	January 2024	August 2025
Yunzhuan Hou	Graduate	Scholarly work	Formal, Research mentor/advisor/coach	March 2023	June 2026
Oluwaseun Adeyanju	Fellow or Post-Doc	Scholarly work	Formal, Research mentor/advisor/coach	November 2019	December 2025

GRANTS

Completed

Federal

RUNX3 in vascular wall remodeling-Diversity Supplement, Funded by NIH/NHLBI (December 15, 2025), awarded August 15, 2024 **\$42,510.00**), Completed, December 2025, CoInvestigator Guoqing Qian [Type of Grant: Research]

University

Novel role of DOCK2 in pulmonary fibrosis , Funded by UT Tyler SOM (September 1, 2025 - May 31, 2026), awarded September 1, 2025 **\$30,000.00**), Completed, September 2025, PI Guoqing Qian (5%) [Type of Grant: Research]

Funded - In Progress

Federal

R01: DOCK2 in pleural fibrosis, Funded by NIH/NHLBI (March 1, 2024 - March 31, 2028), awarded March 1, 2024 **\$1,449,222.00**), Funded - In Progress, March 2024, PI Guoqing Qian (50%) [Type of Grant: Research]

R01: RUNX3 in vascular wall remodeling, Funded by NIH/NHLBI (January 1, 2024 - December 31, 2028), awarded January 1, 2024 **\$2,128,925.00**), Funded - In

SCHOLARLY CONTRIBUTIONS AND CREATIVE PRODUCTIONS

Journal Article

Completed/Published

Peer-reviewed

1. Olajuyin, A., Mandlem, V., Sunil, C., Hou, Y., Adeyanju, O., Petkar, S., Li, Q., Tucker, T. A., Idell, S., Chen, S.-Y. Y., Guo, X., & Qian, G. (2025). BRD4 Mediates Transforming Growth Factor- β -Induced Smooth Muscle Cell Differentiation from Mesenchymal Progenitor Cells. *International Journal of Molecular Sciences*, 26(16).

Abstract, Case Report

Completed/Published

Peer-reviewed

1. Qian, G., Kumar, A., Adeyanju, O., Hou, Y., Shi, J., Li, Q., Idell, S., Tucker, T. A., & Guo, X. (2026). TNIK mediates mesenchymal transition of pleural mesothelial cells. *American Journal of Respiratory and Critical Care Medicine*
2. Kumar, A., Adeyanju, O., Hou, Y., Shi, J., Li, Q., Idell, S., Tucker, T. A., Guo, X., & Qian, G. (2026). TNIK is a novel mediator of pleural mesothelial to mesenchymal transition. *Research Day*.
3. Shi, J., Adeyanju, O., Hou, Y., Li, Q., Guo, X., & Qian, G. (2026). DOCK2 Promotes Lung Fibroblast Proliferation via AKT/GSK3 β / β -Catenin and mTORC1/p70S6K Signaling. *Research Day*.
4. Hou, Y., Adeyanju, O., Shi, J., Kumar, V., Tang, H., Qian, G., & Guo, X. (2026). RUNX3 is a novel regulator for VSMC phenotypic modulation and vascular remodeling. *Research Day*.
5. Kumar, A., Sai, B., Hou, Y., Adeyanju, O., Guo, X., & Qian, G. (2025). DOCK2 mediates macrophage oxidative stress in obesity associated lung injury. *41st Southern Biomedical Engineering Conference*.
6. Lopez, J., Hou, Y., Adeyanju, O., Qian, G., & Guo, X. (2025). Targeting Bromodomain-containing Protein 4 in Abdominal Aortic Aneurysm. *41st Southern Biomedical Engineering Conference*.

Accepted

Peer-reviewed

7. Guo, X., Hou, Y., Lopez, J., & Qian, G. (2026). ARV-825, a BRD4 PROTAC that inhibits angiotensin II-induced abdominal aortic aneurysm. *Circulation*.

Oral Presentations, Symposia, Seminars

Completed/Published

Non-peer Reviewed

1. Qian, G. (2026). Deducator of Cytokinesis 2 in lung injury and repair. *UTHCT Department Seminar*.

Posters

Completed/Published

Peer-reviewed

1. Qian, G., Kumar, A., Adeyanju, O., Hou, Y., Shi, J., Li, Q., Idell, S., Tucker, T. A., & Guo, X. (2026). TNIK mediates mesenchymal transition of pleural mesothelial cells. *ATS Annual Meeting*.
2. Kumar, A., Sai, B., Hou, Y., Adeyanju, O., Guo, X., & Qian, G. (2025). DOCK2 mediates macrophage oxidative stress in obesity associated lung injury. *41st Southern Biomedical Engineering Conference*.

Non-peer Reviewed

3. Kumar, A., Adeyanju, O., Hou, Y., Shi, J., Li, Q., Idell, S., Tucker, T. A., Guo, X., & Qian, G. (2026). TNIK is a novel mediator of pleural mesothelial to mesenchymal transition. *Research Day*.
4. Shi, J., Adeyanju, O., Hou, Y., Li, Q., Guo, X., & Qian, G. (2026). DOCK2 Promotes Lung Fibroblast Proliferation via AKT/GSK3 β / β -Catenin and mTORC1/p70S6K Signaling. *Research Day*.
5. Hou, Y., Adeyanju, O., Shi, J., Kumar, V., Tang, H., Qian, G., & Guo, X. (2026). RUNX3 is a novel regulator for VSMC phenotypic modulation and vascular remodeling. *Research Day*.

Reviewer (Manuscript, Study Section)

Completed/Published

Additional Activities

1. Qian, G. (2025). Functional evaluation of fibroblast-to-myofibroblast transition as an in vitro screening tool for pulmonary fibrosis. *Food and Chemical Toxicology*.
2. Qian, G. (2026). Biomedical Research Proposal . *Politecnico Di Milano, Georgia State University/NBER, and the University of Florida and Novo Nordisk Foundation*.
3. Qian, G. (2026). Myofibroblast-derived extracellular vesicles drive profibrotic cascade amplification in pulmonary fibrosis via Nestin-Rab7 axis. *Journal of Extracellular Vesicles*.
4. Qian, G. (2026). J1017 sensitizes EGFR-T790M NSCLC to erlotinib by extinguishing the STAT3-survivin axis. *Integrative Cancer Therapies*.
5. Qian, G. (2025). DOCK2 in Disease: Emerging Insights and Research Advances. *Immunological Investigations*.

PROFESSIONAL DEVELOPMENT

May 2026 - May 2026

2026 ATS International Meeting, The American Thoracic Society, Orlando, FL

April 2026 - April 2026

2026 Research Day, UTTSOM, UTTSOM

September 2025 - September 2025

41st Southern Biomedical Engineering Conference 2025, UT Tyler, Tyler Texas

September 2019 - Ongoing

Department Seminar , UTTSOM, UTTHSC

